Carvedilol Orion 6.25 mg tabletti, kalvopäällysteinen فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

carvedilol orion 6.25 mg tabletti, kalvopäällysteinen

aurobindo pharma (malta) ltd - carvedilol - tabletti, kalvopäällysteinen - 6.25 mg - karvediloli

Carvedilol Orion 12.5 mg tabletti, kalvopäällysteinen فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

carvedilol orion 12.5 mg tabletti, kalvopäällysteinen

aurobindo pharma (malta) ltd - carvedilol - tabletti, kalvopäällysteinen - 12.5 mg - karvediloli

Carvedilol Orion 25 mg tabletti, kalvopäällysteinen فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

carvedilol orion 25 mg tabletti, kalvopäällysteinen

aurobindo pharma (malta) ltd - carvedilol - tabletti, kalvopäällysteinen - 25 mg - karvediloli

Nitisinone MDK (previously Nitisinone MendeliKABS) الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

nitisinone mdk (previously nitisinone mendelikabs)

mendelikabs europe ltd - nitisinoni - tyrosinemias - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - aikuinen ja lapsille (in iän vaihteluväli) potilailla, joilla on vahvistettu diagnoosi perinnöllinen tyrosinemia tyyppi 1 (ht 1) yhdessä dieettiä tyrosiini ja fenyylialaniini.

Kesimpta الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

kesimpta

novartis ireland ltd - ofatumumab - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

Firmagon الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degareliksia - prostatiset kasvaimet - endokriinihoito - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Tobi Podhaler الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

tobi podhaler

viatris healthcare limited - tobramysiini - cystic fibrosis; respiratory tract infections - systeemiset bakteerilääkkeet, - tobi podhaler on tarkoitettu pseudomonas aeruginosan aiheuttaman kroonisen keuhkotulehduksen suppressoivaan hoitoon aikuisilla ja 6-vuotiailla ja sitä vanhemmilla lapsilla, joilla on kystinen fibroosi. katso kohdat 4. 4 ja 5. 1 tietoja eri ikäryhmissä. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Prialt الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

prialt

esteve pharmaceuticals gmbh - tsikonotidin - injections, spinal; pain - kipulääkkeet - zikonotidi on tarkoitettu vaikean kroonisen kivun hoitoon potilailla, jotka tarvitsevat intratekaalisen (it) analgesiaa.

Resolor الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

resolor

takeda pharmaceuticals international ag ireland - prucalopride succinate - ummetus - muut ummetuslääkkeet - resolor on tarkoitettu oireenmukaista hoitoa kroonisen ummetuksen aikuisilla, joille laksatiivit eivät tuo toivottua lievitystä.

Celdoxome pegylated liposomal الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doksorubisiinihydrokloridia - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiset aineet - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).